BHL gets license from Defence Research and Development Organisation (DRDO) to manufacture and market “2-Deoxy-D-Glucose” (2-DG), used in control & treatment of Covid-19.

Bajaj Healthcare Limited (BHL) a leading manufacturer of APIs, Intermediates and Formulations, has received a licence from DRDO to Manufacture and Market of “2-Deoxy-D-Glucose” (2-DG) as approved medication for the treatment of COVID-19 patients.

2-Deoxy-D-Glucose” (2-DG) helps in the faster recovery of hospitalised patients and reduces supplemental oxygen dependence. The drug works by selectively accumulating in the virus-infected cells and prevents virus growth by stopping viral synthesis and energy production. It can be administered only upon prescription and under the supervision of a qualified physician to hospitalised moderate to severe COVI D-19 patients as an adjunct therapy to the existing standard of care.

Commenting on license received from DRDO for “2-Deoxy-D-Glucose”, Mr. Anil Jain, Joint Managing Director, Bajaj Healthcare said “We are pleased to add 2-Deoxy-D-Glucose to our growing product portfolios after receiving license from DRDO. The second waves of coronavirus is more aggressive and bigger in number than the first. Our countries medical infrastructure is really struggling with scarcity of oxygen capacities. We hope the availability of an effective treatment such as 2-Deoxy-D-Glucose (2-GD) will considerably ease the pressure and offer patients much needed and timely therapy option. Most patients ailing from moderate to severe symptoms can benefit from the use of Deoxy-D-Glucose.”

The Defence Research and Development Organisation (DRDO) has granted permissions to manufacture and market the ““2-Deoxy-D-Glucose”” in the domestic market.